For Healthcare Professionals

ACP-196 (Acalabrutinib) in Combination With Pembrolizumab, for Treatment of Hematologic Malignancies


About the study

This study is evaluating the safety, pharmacodynamics (PD), and efficacy of acalabrutinib and pembrolizumab in hematologic malignancies.

Who can take part

You may be eligible to participate in the study if you meet the following criteria:


Main Inclusion Criteria:

  1. Diagnosis of a hematologic malignancy as documented by medical records and with histology based on criteria established by the World Health Organization (WHO).
  2. Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 1.
  3. Agreement to use contraception during the study and for 90 days after the last dose of ACP-196 or 120 days after the last dose of pembrolizumab, if sexually active and able to bear or beget children.
  4. Completion of all therapy (including surgery, radiotherapy, chemotherapy, immunotherapy, or investigational therapy) for the treatment of cancer ≥ 4 weeks before the start of study therapy.
  5. ANC ≥ 0.5 x 10^9/L or platelet count ≥ 50 x 10^9/L unless due to disease involvement in the bone marrow.


Main Exclusion Criteria:

  1. A life-threatening illness, medical condition or organ system dysfunction which, in the investigator's opinion, could compromise the subject's safety, interfere with the absorption or metabolism of study drugs, or put the study outcomes at undue risk.
  2. Central nervous system (CNS) involvement by lymphoma/leukemia
  3. Any therapeutic antibody within 4 weeks of first dose of study drugs.
  4. Total bilirubin > 1.5 x ULN; and aspartate aminotransferase (AST) or alanine aminotransferase (ALT) > 3.0 x ULN.
  5. Estimated creatinine clearance of < 30 mL/min, calculated using the formula of Cockcroft and Gault (140-Age) • Mass (kg)/(72 • creatinine mg/dL); multiply by 0.85 if female.

pin location

Study Locations

Enter your ZIP code/Postal code/PIN code to locate study sites near you:

How to Apply

Contact the study center to learn if this study is a good match for you.

Study’s details


Follicular Lymphoma (FL),CLL,Small Lymphocytic Lymphoma (SLL),Richter's Syndrome,Mantle Cell Lymphoma (MCL),Indolent Non Hodgkin Lymphoma,Waldenström Macroglobulinemia,Multiple Myeloma,Hodgkin Lymphoma,Burkitt Lymphoma,Marginal Zone Lymphomas,Mediastinal Large B Cell Lymphoma,Hairy Cell Leukemia

Age (in years)



Phase 1/Phase 2

Participants needed


Est. Completion Date

Dec 31, 2025

Treatment type



Acerta Pharma BV identifier


Study number


Understanding Clinical Trials

Get answers to your questions about clinical trials.What is a clinical research?What does taking part in clinical trials involve?What should I ask the trial doctor?


Sign up to save your favorites, 
receive newsletters, resources, and alerts 
about clinical trials related to your conditions of interest.